Gross Profit Margin in Pharmaceuticals & Healthcare
How to interpret and apply gross profit margin when analyzing pharmaceuticals & healthcare stocks in US (NYSE/Nasdaq) markets, with reference to international markets like India.
Quick Recap: What is Gross Profit Margin?
Gross margin shows the percentage of revenue remaining after deducting the direct cost of producing goods or services, the first measure of pricing power.
How Gross Profit Margin Works Differently in Pharmaceuticals & Healthcare
R&D intensive, regulatory risk (USFDA), patent cliffs, mix of domestic and export revenue.
Typical Ranges for Pharmaceuticals & Healthcare
General benchmark: US sector benchmarks: Software/SaaS 70–85%, Pharma/Biotech 60–80%, Consumer Staples 30–45%, Industrials 25–35%, Energy/Materials 20–35%. Or international markets like India: IT/Software 60–80%, FMCG 40–60%, Manufacturing 20–40%.
Sector data last reviewed: 2026-04
Example Pharmaceuticals & Healthcare Companies to Analyze
Filter pharmaceuticals & healthcare stocks by gross profit margin and other metrics:
Key Takeaways
- Gross Profit Margin in pharmaceuticals & healthcare should be compared against sector peers in the same market (US S&P 500 / Russell or Indian NSE / BSE), not the broad market average.
- Sector characteristics: R&D intensive, regulatory risk (USFDA), patent cliffs, mix of domestic and export revenue.
- Cross-list peers across markets, large-cap US names often set the global benchmark, while Indian peers can trade at different multiples due to growth and liquidity differences.
- Always cross-check with other metrics. No single ratio tells the full story.